Research Analysts’ Weekly Ratings Changes for Vaxcyte (PCVX)

Several brokerages have updated their recommendations and price targets on shares of Vaxcyte (NASDAQ: PCVX) in the last few weeks:

• 4/8/2025 – Vaxcyte had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $90.00 price target on the stock.
• 4/1/2025 – Vaxcyte had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $138.00 to $100.00. They now have a “buy” rating on the stock.
• 4/1/2025 – Vaxcyte had its price target lowered by analysts at Bank of America Co. from $157.00 to $137.00. They now have a “buy” rating on the stock.
• 4/1/2025 – Vaxcyte had its price target lowered by analysts at Needham & Company LLC from $140.00 to $90.00. They now have a “buy” rating on the stock.
• 3/31/2025 – Vaxcyte was upgraded by analysts at Evercore ISI to a “strong-buy” rating.
• 3/12/2025 – Vaxcyte had its “buy” rating reaffirmed by analysts at Guggenheim. They now have a $160.00 price target on the stock.
• 2/26/2025 – Vaxcyte had its “buy” rating reaffirmed by analysts at Guggenheim. They now have a $160.00 price target on the stock.
• 2/26/2025 – Vaxcyte had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $140.00 price target on the stock.
• 2/11/2025 – Vaxcyte had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $14.00 price target on the stock.

Vaxcyte Price Performance

Shares of PCVX traded down $2.29 during mid-day trading on Thursday, reaching $28.51. 460,917 shares of the company’s stock traded hands, compared to its average volume of 1,170,940. The stock’s 50-day moving average is $68.64 and its two-hundred day moving average is $86.91. The stock has a market cap of $3.67 billion, a P/E ratio of -6.20 and a beta of 1.26. Vaxcyte, Inc. has a 12 month low of $27.80 and a 12 month high of $121.06.

Vaxcyte (NASDAQ:PCVX) last announced its quarterly earnings results on Tuesday, February 25th. The company reported ($1.02) EPS for the quarter, beating the consensus estimate of ($1.16) by $0.14. Research analysts predict that Vaxcyte, Inc. will post -4.21 earnings per share for the current year.

Insider Activity

In other news, Director Teri Loxam sold 6,250 shares of the business’s stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $85.11, for a total transaction of $531,937.50. Following the sale, the director now owns 7,175 shares in the company, valued at approximately $610,664.25. The trade was a 46.55 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Jim Wassil sold 8,000 shares of Vaxcyte stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $86.22, for a total transaction of $689,760.00. Following the completion of the sale, the chief operating officer now owns 205,695 shares of the company’s stock, valued at $17,735,022.90. This trade represents a 3.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 38,250 shares of company stock worth $3,170,738. Corporate insiders own 3.10% of the company’s stock.

Institutional Investors Weigh In On Vaxcyte

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Whipplewood Advisors LLC acquired a new position in Vaxcyte in the 4th quarter worth about $28,000. Smartleaf Asset Management LLC lifted its position in shares of Vaxcyte by 188.4% during the 4th quarter. Smartleaf Asset Management LLC now owns 398 shares of the company’s stock valued at $33,000 after buying an additional 260 shares in the last quarter. National Bank of Canada FI acquired a new stake in Vaxcyte in the 4th quarter valued at $41,000. Blue Trust Inc. raised its position in Vaxcyte by 100.0% during the fourth quarter. Blue Trust Inc. now owns 742 shares of the company’s stock worth $61,000 after acquiring an additional 371 shares during the period. Finally, Assetmark Inc. grew its position in shares of Vaxcyte by 77,500.0% in the fourth quarter. Assetmark Inc. now owns 776 shares of the company’s stock valued at $64,000 after purchasing an additional 775 shares during the period. 96.78% of the stock is owned by institutional investors and hedge funds.

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.